GSK adds detailed clinical trial data to multi-sponsor request system

GlaxoSmithKlineGlaxoSmithKline (GSK) has added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system that includes studies from multiple organisations.

Last year GSK became the first company to launch an online system enabling external researchers to request access to the detailed data that sit behind its clinical trial results. More than 450 studies have now been made available on the new site. GSK's patient-level data transparency commitments remain unchanged through the new multi-sponsor request system:

  • GSK is continuing to post studies going back to the formation of GSK in 2000.
  • Studies are made available once a medicine has been approved by regulators or terminated from development and the study has been accepted for publication (studies that do not progress to publication will also be included).
  • Researchers can ask about the availability of data they are interested in from studies not yet listed on the site.
  • The arm's length review panel who have been reviewing proposals through GSK’s site since May 2013 will continue its role and will now review proposals that include studies from other sponsors. Up to 30 November 2013, 16 requests for data had been received by the review panel. 12 requests had been approved, with four being processed. None had been turned down.

GSK will regularly add studies to the site. The next major update, when additional new and historic studies will be added, is planned for Q1 2014.

James Shannon, GSK's Chief Medical Officer, said: "Our commitment to transparency of clinical trial data reflects our wish to help advance scientific understanding and enable the scientific community to learn from the research we have undertaken. Enabling researchers to request the studies they are interested in from multiple organisations through one system will, we hope, help further research.

"Our ultimate aim remains unchanged and that is to see a broad system developed that brings together data from many organisations and is also run by an independent third party who would be responsible for managing the review of research proposals. This initiative is an important step towards that aim."

GSK has taken a number of steps over the years to share more information from clinical trials that evaluate its medicines:

  • The company registers and posts summary information about each clinical trial it begins.
  • Results of all clinical trials - whether positive or negative - are made available on a website accessible to all. Today this website includes almost 5,000 clinical trial result summaries and receives an average of almost 11,000 visitors each month.
  • The company has also committed to seek publication of the results of all of its clinical trials that evaluate its medicines in peer-reviewed scientific journals.
  • In February 2013, GSK signed up to the AllTrials campaign for clinical data transparency and committed to make its clinical study reports (CSRs) publicly available through its clinical trials register after approval, termination and publication. CSRs are formal study reports that provide more details on the design, methods and results of clinical trials and form the basis of submissions to regulatory agencies.
  • In May 2013 GSK became the first organisation to launch an online system enabling external researchers to request access to anonymised patient-level data from its clinical trials.

The new multi-sponsor site, clinicalstudydatarequest.com, has been launched by the enterprise software provider ideaPoint, which provides the technology behind the site's secure request and evaluation process.

About GlaxoSmithKline
One of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better, and live longer.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...